ACE Convergence Acquisition Corp.

ACE Convergence Acquisition Corp.

ACEVU
ACE Convergence Acquisition Corp.US flagNASDAQ Capital Market
9.77
USD
-0.01
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChatGPT
CEO
Behrooz Abdi
Sector
Financial Services
Industry
Shell Companies
Address
1013 Centre Road Wilmington DE United States of America 19805
IPO Date
Jul 28, 2020
Website
acev.io
Business
ACE Convergence Acquisition Corp. was formerly established as a special purpose acquisition company, or SPAC, in 2020, primarily focusing on identifying and merging with businesses within the information technology infrastructure software and semiconductor sectors. The company did not conduct substantial operational activities of its own, instead aiming to complete a significant business combination. Following this strategy, the entity successfully completed a reverse merger transaction with Tempo Automation Holdings, Inc., an electronics manufacturer, in November 2022. Subsequent to this business combination, ACE Convergence Acquisition Corp. transitioned into Tempo Automation Holdings, Inc., with the combined entity's common stock and warrants commencing trade on Nasdaq under the new ticker symbols TMPO and TMPOW, respectively.

Company News

APIChatGPT
  • U.S. IPO Week Ahead: Tax Software Leads A Diverse 7-IPO Week

  • U.S. IPO Weekly Recap: Preclinical Biotech Nkarta Pops 166% In A 5 IPO Week